is a popular medicinal website in Bangladesh.



Generic name: Pantoprazole
Therapeutic Group: Gastro Intestinal Disorders » Antiulcerant » PPI
Manufacturer: Incepta Pharmaceuticals Ltd.

Pantoprazole (Pantonix) is chemically a novel substituted benzimidazole derivative, which suppresses the final step in gastric acid production by forming a covalent bond to two sites of the H+, K+ - ATPase enzyme system at the secretory surface of the gastric parietal cell. This leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the H+, K+ - ATPase results in duration of antisecretory effect that persists longer than 24 hours. Pantoprazole (Pantonix) is quantitatively absorbed and bioavailability does not change upon multiple dosing. Pantoprazole (Pantonix) is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion.

Pantoprazole (Pantonix) is indicated where suppression of acid secretion is of therapeutic benefit. Pantoprazole (Pantonix) is registered for the following indications: -

1. Peptic ulcer diseases (PUD)
2. Gastro esophageal reflux diseases (GERD)
3. Treatment of ulcer resistant to H2 receptor antagonists (H2RAs)
4. Treatment of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs)
5. Gastrointestinal (GI) bleeding from stress or acid peptic diseases
6. Eradication of Helicobacter pylori (in combination with antibiotics)
7. Zollinger-Ellison syndrome
8. Prophylaxis for acid aspiration syndrome during induction of anaesthesia

Patients should be cautioned that Pantonix delayed release tablets should not be split, chewed or crushed.


Post a Comment

Note: Only a member of this blog may post a comment.